FMT in IT-refractory HCC - FAB-HCC Pilot Study
NCT05750030
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
12
Enrollment
OTHER
Sponsor class
Conditions
Hepatocellular Carcinoma
Interventions
COMBINATION_PRODUCT:
FMT combined with Atezolizumab plus Bevacizumab
Sponsor
Medical University of Vienna